Statin effects on CRPC: Evidence from the SPECTRE trial

What is it about?

The SPECTRE trial was a 6-week long Phase II treatment trial that combined atorvastatin and androgen deprivation therapy in patients with castration-resistant prostate cancer (CRPC). The primary study endpoint was the proportion of patients achieving a ≥50% drop from baseline in prostate-specific antigen (PSA) levels at any time over the 6-week period of atorvastatin medication (PSA response). The study found that one of 12 patients experienced a ≥50% drop in PSA levels, and all 12 patients experienced substantial falls in serum cholesterol levels following statin treatment. Six of 12 patients showed decreased PSA velocities after statin treatment, suggestive of disease stabilization. Unbiased metabolomics analysis on serial weekly blood samples identified tryptophan to be the dominant metabolite associated with patient response to statin. The study provides the first evidence of statin-mediated effects on CRPC and early sign of disease stabilization.

Featured Image

Why is it important?

The study is important as it provides the first evidence of statin-mediated effects on castration-resistant prostate cancer (CRPC) and suggests early signs of disease stabilization. This has implications for the potential use of statins as a treatment for advanced prostate cancer, which could improve patient outcomes. Key Takeaways: 1. The SPECTRE trial was a 6-week-long proof-of-concept single-arm Phase II treatment trial that tested the effects of atorvastatin in combination with androgen deprivation therapy on patients with CRPC. 2. The primary study endpoint was the proportion of patients achieving a ≥50% drop from baseline in prostate-specific antigen (PSA) levels at any time over the 6-week period of atorvastatin medication. 3. Exploratory endpoints include PSA velocity and serum metabolites identified by mass spectrometry. 4. At the scheduled interim analysis, one of 12 patients experienced a ≥50% drop in PSA levels, with ≥2 patients satisfying the primary endpoint required for further recruitment. 5. All 12 patients experienced substantial falls in serum cholesterol levels following statin treatment. 6. Unbiased metabolomics analysis on serial weekly blood samples identified tryptophan to be the dominant metabolite associated with patient response to statin. 7. The study highlights the possibility of altered tryptophan metabolism being associated with tumor response.